Vernalis Achieves Milestone Under Novartis Collaboration
Vernalis said that the $3m milestone is triggered by the first dosing in a Phase II clinical trial of an Hsp90 inhibitor AUY-922, in a range of solid
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
Reportedly, numerous published studies showed the benefits of GLA supplementation, including anti-inflammatory effects, and improved skin health and appearance. A recent study by Schirmer and Phinney found that